Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.
暂无分享,去创建一个
B. Asselain | J. Pierga | P. Beuzeboc | A. Fourquet | P. Pouillart | S. Scholl | T. Dorval | M. Jouve | T. Palangié | E. Garcia-Giralt | Y. Remvikos | J. Durand | J. Pierga
[1] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[2] K. Cowan,et al. Antineoplastic Drug Resistance and Breast Cancer , 1993, Annals of the New York Academy of Sciences.
[3] H. Magdelenat,et al. Prognostic Value of the S‐Phase Fraction of Breast Cancers Treated by Primary Radiotherapy or Neoadjuvant Chemotherapy , 1993, Annals of the New York Academy of Sciences.
[4] R. Arceci. Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments] , 1993 .
[5] B. Asselain,et al. Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.
[6] D. Schaid,et al. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. McGuire,et al. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement , 1992, Cancer.
[8] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Frierson. Ploidy Analysis and S‐Phase Fraction Determination by Flow Cytometry of Invasive Adenocarcinomas of the Breast , 1991, The American journal of surgical pathology.
[11] L. Case,et al. The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients , 1990, Cancer.
[12] J. Schneider,et al. P-glycoprotein expression in treated and untreated human breast cancer. , 1989, British Journal of Cancer.
[13] H. Magdelenat,et al. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. , 1989, Journal of the National Cancer Institute.
[14] S. Ménard,et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients , 1988, Cancer.
[15] A. Zajdela,et al. DNA flow cytometry applied to fine needle sampling of human breast cancer , 1988, Cancer.
[16] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[17] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[18] B. Asselain,et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.